Acadian Asset Management
NGM

Acadian Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Acadian Asset Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,339,331
Closed -$1.15M – 1849
2023
Q4 		$1.15M Buy
1,339,331
+145,360
+12% +$128K ﹤0.01% 820
2023
Q3 		$1.28M Buy
1,193,971
+55,128
+5% +$114K 0.01% 805
2023
Q2 		$2.95M Buy
1,138,843
+200,409
+21% +$715K 0.01% 598
2023
Q1 		$3.82M Buy
938,434
+357,211
+61% +$1.65M 0.02% 525
2022
Q4 		$2.91M Buy
+581,223
New +$3.64M 0.01% 580
2022
Q3 		– Sell
-16,716
Closed -$214K – 1896
2022
Q2 		$214K Buy
16,716
+1,563
+10% +$21.6K ﹤0.01% 1179
2022
Q1 		$230K Buy
15,153
+13,413
+771% +$209K ﹤0.01% 1178
2021
Q4 		$30K Buy
+1,740
New +$33.4K ﹤0.01% 1561
2021
Q3 		– Sell
-4,305
Closed -$85K – 2087
2021
Q2 		$85K Buy
+4,305
New +$101K ﹤0.01% 1675
2020
Q3 		– Sell
-9,452
Closed -$186K – 2403
2020
Q2 		$186K Buy
9,452
+4,109
+77% +$78.5K ﹤0.01% 1521
2020
Q1 		$66K Buy
+5,343
New +$87.2K ﹤0.01% 1450

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management's NGM Position: Q1 2024 in Review

Acadian Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 1,339,331 shares — an estimated $1.15M sold.

Acadian Asset Management first reported a position in NGM in Q1 2020 and held it in 11 quarters. The position peaked at $3.82M in Q1 2023. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Acadian Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Acadian Asset Management sold 1,339,331 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $1.15M.
  • Acadian Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • Acadian Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $3.82M in Q1 2023.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.